Avellino Lab

Avellino Lab USA, Inc. is a global leader in molecular diagnostics at the forefront of precision medicine for eye care. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. The company is the maker of AvaGen™, The Genetic Eye Test. AvaGen quantifies the risk or presence of keratoconus and other corneal genetic disorders caused by gene variants. AvaGen delivers a valuable tool for early and accurate decision-making that protects vision for patients and their families. Avellino also developed the SARS-CoV-2 RT-PCR diagnostic test (AvellinoCoV2) to aid in COVID-19 pandemic testing efforts in the US and was the first private, independent company in the US to receive an EUA for its COVID-19 test. Avellino is headquartered in Menlo Park, California, with operations in Korea, Japan, and UK with future plans for further expansion in both Asia and Europe. To learn more about Avellino, visit www.avellino.com.